ACTRN12618001858280
Terminated
Phase 4
Randomized Evaluation of Beta Blocker and Angiotensin Converting Enzyme Inhibitor (ACEI) /Angiotensin Receptor Blocker (ARB) Treatment in MINOCA Patients.
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Myocardial Infarction With Non-obstructive Coronary Arteries
- Sponsor
- The University of Adelaide
- Enrollment
- 71
- Status
- Terminated
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age equal or greater than 18 years.
- •2\. A clinical diagnosis of MINOCA, including:
- •a. Acute myocardial infarction – as per the universal myocardial infarction Criteria (Thygesen et al, 2018\)
- •b. Non\-obstructive coronary arteries – no lesion equal or greater than 50% in the potential infarct\-related artery.
- •c. No overt non\-ischaemic cause for the acute clinical presentation.
- •3\. Left ventricle ejection fraction equal or less than 40% \- assessed by echocardiography, MRI or left ventriculography prior to
- •randomisation.
- •4\. Written informed consent obtained
Exclusion Criteria
- •Any condition that may influence the patient's ability to comply with study protocol.
- •2\. Pregnancy
- •3\. Previous revascularization (CABG or PCI)
- •4\. Myocarditis Diagnosis (Cardiac MRI proved myocarditis or a strong clinical suspicion
- •of myocarditis as a cause of the index event)
- •5\. Clinical signs of heart failure
- •6\. Contraindications for ACEI and ARB
- •7\. Contraindications for beta\-blockers
- •8\. Prior use of ACE\-I, ARB, or beta blockers, which must continue as per treating
- •9\. New indication for beta\-blockers or ACEI/ARB other than as secondary prevention as
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Registry based randomized study of Beta blocker, ACE Inhibitor and Angiotensin Receptor Blocker in patients discharged with myocardial infarction with non-obstructive coronary artery disease (MINOCA-BAT)Myocardial infarction with non-obstructive coronary artery disease (MINOCA).Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-000889-11-SEDepartment of Medical Sciences, Uppsala Universitet3,500
Active, not recruiting
Phase 1
Registry based randomized study of Beta blocker, ACE Inhibitor and Angiotensin Receptor Blocker in patients discharged with myocardial infarction with non-obstructive coronary artery disease (MINOCA-BAT)Myocardial infarction with non-obstructive coronary artery disease (MINOCA).Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-000889-11-NODepartment of Medical Sciences, Akademiska sjukhuset3,500
Active, not recruiting
Phase 1
Registry based randomized study of Beta blocker, ACE Inhibitor and Angiotensin Receptor Blocker in patients discharged with myocardial infarction with non-obstructive coronary artery disease (MINOCA-BAT)Myocardial infarction with non-obstructive coronary artery disease (MINOCA).Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-000889-11-ESDepartment of Medical Sciences, Uppsala Universitet3,500
Recruiting
Phase 3
The effect of a combination of beta-blockers, angiotensin receptor blockers, and calcium channel blockers in aortic stenosisAortic stenosisCardiovascular - Other cardiovascular diseasesACTRN12621001732875niversity of Otago1,250
Recruiting
Phase 3
Investigating the effectiveness of beta-blocker on hypermetabolic response in adult patients due to acute burnsIRCT20230301057584N1Bandare-abbas University of Medical Sciences90